Community-acquired pneumonia. Clinical recommendations. Yesterday, today and tomorrow. To the article (round-table discussion: physician, pulmonologist, clinical pharmacologist)
- Authors: Dvoretsky L.I.1, Iakovlev S.V.1, Karnaushkina M.A.1
- 
							Affiliations: 
							- I.M.Sechenov First Moscow State Medical University (Sechenov University)
 
- Issue: Vol 21, No 3 (2019)
- Pages: 9-14
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/96863
- DOI: https://doi.org/10.26442/20751753.2019.3.190210
- ID: 96863
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Leonid I. Dvoretsky
I.M.Sechenov First Moscow State Medical University (Sechenov University)
														Email: dvoretski@mail.ru
				                					                																			                								D. Sci. (Med.), Full Prof.				                								Moscow, Russia						
Sergei V. Iakovlev
I.M.Sechenov First Moscow State Medical University (Sechenov University)д-р мед. наук, проф. каф. госпитальной терапии №2; резидент Альянса клинических химиотерапевтов и микробиологов Moscow, Russia
Mariia A. Karnaushkina
I.M.Sechenov First Moscow State Medical University (Sechenov University)
														Email: kar3745@yandex.ru
				                					                																			                								д-р мед. наук, проф. каф. госпитальной терапии №2				                								Moscow, Russia						
References
- Welte T et al. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67 (1): 71-9.
- Fine M.J et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275 (2): 134-41.
- Taboada M et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother 2016; 71 (4): 862-70.
Supplementary files
 
				
			 
					 
						 
				

